Roth Capital "Assumes" Conatus Pharmaceutic (NASDAQ:CNAT) in a research note issued to investors on 7/01/16 to Buy. FBR & Co reissued an outperform rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research report on Wednesday, March 15th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the past year is $14.50.
Conatus Pharmaceuticals (NASDAQ CNAT) traded down 7.10% during midday trading on Thursday, hitting $5.76. The company's stock had a trading volume of 559,896 shares. The share price has moved forward from its 20 days moving average, trading at a distance of 10.44% and stays -7.53% away from its 50 days moving average.
Conatus Pharmaceuticals Inc. has a 168.45M market cap and its past year revenues were 7.80M. (NASDAQ:CNAT) was up 2.56% at $5.60 on Wednesday, in a 52-week range of $1.45 to $9.40 and with a consensus analyst target price of $15.17. The stock of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has "Buy" rating given on Thursday, November 5 by Stifel Nicolaus. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.20. In comparison, a year ago the company earned revenue of $0 and had a GAAP net loss of $6.47 million.
Washington approves $1.3 bn arms sale to Taiwan
But analysts said the promised sale was more of a political gesture and would not have much real impact on Taiwan's defences. Navy to the Taiwanese port of Kaohsiung, or any other suitable port, and would allow the U.S.
The company has mean EPS estimate of -0.17 reported by 6 number of analyst for the quarter ending Current Qtr.(Jun2017).
A number of other large investors have also recently added to or reduced their stakes in the company. Morgan Stanley raised its position in Conatus Pharmaceuticals by 265.6% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company's stock worth $464,000 after buying an additional 1,655 shares in the last quarter. The Northpointe Capital Llc holds 309,100 shares with $11.34 million value, up from 213,362 last quarter. Its book value per share for the most recent quarter is $0.74 while its price to book ratio for the same period is 8.38, as for as the company's cash per share for the most recent quarter is $2.68, however its price to cash per share ratio for the same period is 2.31. Geode Capital Management LLC boosted its stake in shares of Conatus Pharmaceuticals by 21.4% in the first quarter. California-based Blackrock Institutional Trust Communication Na has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). ING Groep NV acquired a new stake in shares of Conatus Pharmaceuticals during the fourth quarter worth approximately $110,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Conatus Pharmaceuticals by 2.1% in the first quarter. Vanguard Group Inc. now owns 767,517 shares of the biotechnology company's stock worth $4,428,000 after buying an additional 369,973 shares during the period. Susquehanna Group Incorporated Limited Liability Partnership reported 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). "(CNAT) Short Interest Update" was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of United States and worldwide trademark & copyright legislation. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Sucampo Pharmaceuticals. The Firm focuses on the development and commercialization of medicines to treat liver disease.